ESMO 2016 Congress

Oncology Meeting Resources

07 Oct - 11 Oct 2016, Copenhagen, Denmark

ESMO-Congress-2016-square

The annual ESMO congress is the premier scientific platform to present your oncology research and as such, the ultimate learning experience for congress attendees. Find the abstracts, posters, PDF presentation and webcasts from ESMO 2016 to the extent the presenters have consented to release their contribution or a slightly modified version thereof. Please, note that the publication of these presentations is a courtesy of the originating authors and is for personal educational purposes only.

Special Sessions and Tracks

Useful links





Format available

https://oncologypro.esmo.org/Meeting-Resour...eatic-cancer-LAPC-Final-analysis-of-JCOG1106

BackgroundJCOG1106 is a phase II trial to evaluate the efficacy and safety of chemoradiotherapy (CRT) with and without induction chemotherapy (CT) to determine which is more promising CRT regimen for LAPC.

Date: 08 Oct 2016
Presenter: Tatsuya Ioka
Resources: Abstract
Topics: Anticancer Agents, Pancreatic Cancer, Surgical Oncology, Therapy, Biological Therapy, Radiation Oncology

https://oncologypro.esmo.org/Meeting-Resour...ously-treated-with-gemcitabine-based-therapy

Backgroundnal-IRI, a liposomal formulation of irinotecan, plus 5-FU/LV is approved in the US for patients (pts) with mPAC previously treated with gemcitabine-based therapy.

Date: 08 Oct 2016
Presenter: Li-Tzong Chen
Resources: Abstract
Topics: Anticancer Agents, Pancreatic Cancer, Therapy, Biological Therapy

https://oncologypro.esmo.org/Meeting-Resour...tic-cancer-PC-Younger-vs.-older-patients-pts

BackgroundThere is limited data on molecular tumor characteristics and outcome in younger pts with PC. The effect of an individual's age on their tumor molecular profile is unknown.

Date: 08 Oct 2016
Presenter: Mohamed Salem
Resources: Abstract
Topics: Pancreatic Cancer, Translational Research, Basic Principles in the Management and Treatment (of cancer)

https://oncologypro.esmo.org/Meeting-Resour...potentially-resectable-tumours-Final-results

BackgroundLocally advanced pancreatic cancer (LAPC) is often a mix of borderline and never-resectable tumors. Multimodality treatment might downstage these tumors to allow a potential radical resection, especially the borderline group.

Date: 08 Oct 2016
Presenter: Per Pfeiffer
Resources: Abstract
Topics: Pancreatic Cancer, Surgical Oncology, Therapy, Radiation Oncology

https://oncologypro.esmo.org/Meeting-Resour...derline-resectable-pancreatic-adenocarcinoma

BackgroundA phase 1b trial defined the recommended phase 2 dose of nab-paclitaxel (150 mg/m2) in combination with cisplatin, capecitabine, and gemcitabine (800, 30, and 1250 mg/m2 every 2 weeks, respectively; PAXG regimen).

Date: 08 Oct 2016
Presenter: Michele Reni
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...ase-I-dose-finding-of-NabucCO-study-by-GOIRC

BackgroundFOLFIRINOX and nab-paclitaxel (nab-p) plus gemcitabine are effective regimens in first line treatment for metastatic pancreatic cancer (mPC). NabucCO study is designed to define dose limiting...

Date: 08 Oct 2016
Presenter: Elisa Giommoni
Resources: Abstract
Topics: Anticancer Agents, Pancreatic Cancer, Therapy, Biological Therapy

https://oncologypro.esmo.org/Meeting-Resour...ine-chemotherapy-A-population-based-analysis

BackgroundFOLFIRINOX (FFN), nab-paclitaxel plus gemcitabine (NG), and gemcitabine (gem) are 3 systemic therapies that provide clinically meaningful benefit to patients with unresectable pancreatic cancer (UPC).

Date: 08 Oct 2016
Presenter: Ying Wang
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...ctable-pancreatic-ductal-adenocarcinoma-PDAC

BackgroundThere is considerable interest in investigating ctDNA as a non-invasive biomarker, with potential utility in screening, detecting minimal residual disease after curative resection and monitoring treatment response or resistance.

Date: 08 Oct 2016
Presenter: Hui-li Wong
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...apanese-patients-pts-JASPAC-06-final-results

BackgroundFor Japanese pts, there are limited data of a small phase II trial of FFX (Okusaka, Cancer Sci 2014). In this multi-center retrospective study, we previously reported the preliminary results...

Date: 08 Oct 2016
Presenter: Nobumasa Mizuno
Resources: Abstract
Topic: Pancreatic Cancer

https://oncologypro.esmo.org/Meeting-Resour...inox-in-metastatic-pancreatic-adenocarcinoma

BackgroundFolfirinox (FFX) and Nab-paclitaxel/Gemcitabine (AG) showed significant improvement in efficacy compared to Gemcitabine alone in metastatic pancreatic cancer (mPC).

Date: 08 Oct 2016
Presenter: Eric Assenat
Resources: Abstract
Topic: Pancreatic Cancer